Did you actually read that article that spends many pages explaining how there is no good way for a firm to patent a repurposed drug that is working the same way as it worked in a prior indication, but is being used for a new indication where it has the same function - exactly what you’re asserting and what I said is not possible?

Thanks for the article, it is a good one.